
Savara Investor Relations Material
Latest events

Q1 2025
22 Jul, 2025

Corporate Presentation
27 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Savara Inc
Access all reports
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's main focus is on advancing its lead product candidate, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). In addition to molgramostim, Savara is also developing AeroVanc, an inhaled vancomycin aimed at treating methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. Savara is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.
Key slides for Savara Inc


Corporate Presentation
Savara Inc


Corporate Presentation
Savara Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SVRA
Country
🇺🇸 United States